Literature DB >> 20974569

SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.

Delvys Rodríguez-Abreu1, Marta Llanos Muñoz, Mariano Provencio Pulla, Antonio Rueda Domínguez, Dolores Isla Casado.   

Abstract

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin's lymphoma (NHL) in the Western world. FL constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and its morphologic and biologic features. It is often managed as an incurable disease. However, several active therapeutic approaches from the "wait and watch" strategy to the allogeneic transplantation are available for management of patients with FL and clearly have changed the natural history of this disease, achieving a long-term disease-free survival. Therapeutic decision is mostly conditioned by patient's characteristics, stage, histological grade, tumor burden, and risk-predicting factors. This article try to summarizes the diagnosis and treatment of this heterogeneous group of patients.

Entities:  

Mesh:

Year:  2010        PMID: 20974569     DOI: 10.1007/s12094-010-0592-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  17 in total

Review 1.  Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  M Dreyling
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

2.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

3.  Meta-analysis to evaluate the role of interferon in follicular lymphoma.

Authors:  A Z S Rohatiner; W M Gregory; B Peterson; E Borden; P Solal-Celigny; A Hagenbeek; R I Fisher; M Unterhalt; R Arranz; T Chisesi; A Aviles; T A Lister
Journal:  J Clin Oncol       Date:  2005-01-31       Impact factor: 44.544

4.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

Authors:  M S Kaminski; J Estes; K R Zasadny; I R Francis; C W Ross; M Tuck; D Regan; S Fisher; J Gutierrez; S Kroll; R Stagg; G Tidmarsh; R L Wahl
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

5.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

Authors:  Harry C Schouten; Wendi Qian; Stein Kvaloy; Adolfo Porcellini; Hans Hagberg; Hans Erik Johnsen; Jeanette K Doorduijn; Matthew R Sydes; Gunnar Kvalheim
Journal:  J Clin Oncol       Date:  2003-09-29       Impact factor: 44.544

6.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors:  Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

7.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Authors:  K Sue Robinson; Michael E Williams; Richard H van der Jagt; Philip Cohen; Jordan A Herst; Anil Tulpule; Lee S Schwartzberg; Bernard Lemieux; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

9.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

10.  Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy.

Authors:  Ranjana Advani; Saul A Rosenberg; Sandra J Horning
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  2 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

2.  Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review.

Authors:  Tulay Kus; Gokmen Aktas; Mehmet Emin Kalender; Ibrahim Sari; Esra Ulker; Celaletdin Camci
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.